Truvestments Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Truvestments Capital’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-22	Closed	-$29	–	1067
2024 Q3	$29	Buy	+22	New	+$106	﹤0.01%	925
2024 Q2	–	Sell	-22	Closed	-$198	–	729
2024 Q1	$198	Hold	22	–	–	﹤0.01%	701
2023 Q4	$236	Hold	22	–	–	﹤0.01%	763
2023 Q3	$132	Hold	22	–	–	﹤0.01%	671
2023 Q2	$152	Hold	22	–	–	﹤0.01%	679
2023 Q1	$345	Hold	22	–	–	﹤0.01%	644
2022 Q4	$440	Hold	22	–	–	﹤0.01%	873
2022 Q3	$0	Hold	22	–	–	﹤0.01%	665
2022 Q2	$0	Buy	+22	New	+$491	﹤0.01%	656
2022 Q1	–	Sell	-22	Closed	-$1K	–	591
2021 Q4	$1K	Hold	22	–	–	﹤0.01%	595
2021 Q3	$2K	Hold	22	–	–	﹤0.01%	559
2021 Q2	$2K	Hold	22	–	–	﹤0.01%	568
2021 Q1	$4K	Buy	+22	New	+$2.91K	﹤0.01%	554

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Truvestments Capital's ONCT Position: Q4 2024 in Review

Truvestments Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 22 shares — an estimated $29 sold.

Truvestments Capital first reported a position in ONCT in Q1 2021 and held it in 13 quarters. The position peaked at $4K in Q1 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

Truvestments Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Truvestments Capital sold 22 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $29.
Truvestments Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
Truvestments Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $4K in Q1 2021.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Truvestments Capital's 13F filing for Q4 2024, filed 10 Feb 2025.